Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
1.770
+0.010 (0.57%)
At close: Mar 6, 2026, 4:00 PM EST
1.740
-0.030 (-1.69%)
After-hours: Mar 6, 2026, 5:32 PM EST
Equillium Revenue
Equillium had revenue of $4.39M in the twelve months ending September 30, 2025, down -90.43% year-over-year. In the year 2024, Equillium had annual revenue of $41.10M with 13.89% growth.
Revenue (ttm)
$4.39M
Revenue Growth
-90.43%
P/S Ratio
24.54
Revenue / Employee
$125,486
Employees
35
Market Cap
107.78M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 106.83M |
| Fortress Biotech | 62.30M |
| Codexis | 52.93M |
| Gossamer Bio | 44.05M |
| Seer, Inc. | 16.58M |
| Korro Bio | 7.37M |
| Coya Therapeutics | 3.99M |
| Precision BioSciences | 698.00K |
EQ News
- 10 days ago - Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC - Seeking Alpha
- 10 days ago - Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Equillium to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 4 months ago - Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript - Seeking Alpha
- 4 months ago - Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - GlobeNewsWire
- 5 months ago - Equillium Announces Leadership and Corporate Updates - GlobeNewsWire